Pharmaceutical giant Novartis is strategically positioning itself to overcome significant patent expirations, even as its highly anticipated multiple sclerosis (MS) drug, remibrutinib, faces scrutiny over its market potential. The company recently reported improved third-quarter profitability, signaling a successful transition beyond the steepest patent cliff in its history. However, the outlook for remibrutinib, championed by CEO Vas Narasimhan as potentially one of the company’s largest medicines, has been tempered by analyst revisions following late-stage clinical trial results.

While remibrutinib met its primary endpoint in trials for relapsing multiple sclerosis, its efficacy appeared less robust than anticipated by some analysts. Barclays, for instance, reduced its peak sales forecast for the drug. Experts note that while remibrutinib, a BTK inhibitor, offers a potentially favorable safety profile by regulating immune cells rather than depleting them like Novartis’s own Kesimpta, its ability to control relapsing MS may not match that of high-efficacy antibody treatments. This has led to projections of over $4 billion in peak annual sales for remibrutinib in relapsing MS, with broader indications potentially pushing total sales beyond $8 billion.

The company’s strategic focus is also shaped by looming patent expirations for its blockbuster drugs Kisqali and Kesimpta, anticipated around 2032, which together represent an estimated $18 billion in peak sales. Novartis aims to leverage remibrutinib not as a direct replacement for Kesimpta, but as an expansion of its MS portfolio, targeting newly diagnosed patients, those on oral treatments, and individuals on anti-CD20 therapies who might benefit from a switch. The drug also holds potential in progressive MS, where treatment options are limited, with trial results expected in 2031, and has an existing approval for chronic hives, with further trials in hidradenitis suppurativa underway.

Key Takeaways

• Novartis is navigating patent expirations while facing revised sales forecasts for its new MS drug, remibrutinib.
• Remibrutinib shows promise with a potentially favorable safety profile but may be less effective than existing antibody treatments for relapsing MS.
• The company is also preparing for significant patent cliffs for its key drugs Kisqali and Kesimpta around 2032.

Editor’s Analysis & Impact

Novartis is at a critical juncture, balancing the successful management of past patent expirations with the development and market positioning of new therapies like remibrutinib. While the drug offers a novel mechanism of action and potential safety advantages, its commercial success hinges on demonstrating clear differentiation and efficacy against established treatments, particularly as the company faces the substantial revenue loss from upcoming patent expirations on Kisqali and Kesimpta. The market’s focus will be on remibrutinib’s performance in progressive MS and its ability to capture market share in a competitive landscape, alongside its potential in other indications like hidradenitis suppurativa.

Frequently Asked Questions

Q: What is remibrutinib and how does it work?
A: Remibrutinib is an experimental drug belonging to the class of BTK inhibitors. It works by regulating the activity of immune cells that damage nerves in patients with multiple sclerosis, aiming to reduce the autoimmune response without completely eliminating the cells.

Q: What are the main challenges facing remibrutinib?
A: The primary challenges for remibrutinib include its perceived lower efficacy in controlling relapsing MS compared to existing high-efficacy antibody treatments, and revised peak sales forecasts from analysts. Its long-term safety profile also requires further data, and its success will depend on head-to-head comparisons with rival drugs and its ability to secure favorable pricing and market access.

Q: How does Novartis plan to mitigate its upcoming patent cliffs?
A: Novartis is focusing on expanding its drug portfolio and leveraging new therapies like remibrutinib. The company is also looking to capitalize on remibrutinib's potential in different forms of MS and other conditions, while also preparing for the patent expirations of its major drugs Kisqali and Kesimpta around 2032.